CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)

T2DM With Inadequate Glycemic Control Clinical Trial

Official title: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

Status Completed

Clinical Trial Summary

The objective of the study is to compare the efficacy and safety of 3 doses CS02 Tablet in combination with a stable dose of metformin monotherapy against CS02 PTM (placebo) Tablet in combination with a stable dose of metformin monotherapy over a 12 weeks treatment period in subjects with type 2 diabetes mellitus with inadequate glycemic control on metformin alone.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• T2DM With Inadequate Glycemic Control

• NCT number: NCT03317028
• Study type: Interventional
• Source: Center Laboratories, Inc.
• Status: Completed
• Phase: Phase 2
• Start date: October 10, 2017
• Completion date: April 21, 2020